Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

624
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
624
T Cell Types and Functions01:24

T Cell Types and Functions

1.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.2K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

2.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
2.6K
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

56
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
56
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COF-based electrocatalysts for the hydrogen evolution reaction: construction strategies, performance enhancement, and challenges.

Chemical communications (Cambridge, England)·2026
Same author

Transient Thermal Engineering of Pt@rGO Nanocatalysts via Oxygen Anchoring and Chlorine Coordination for Efficient Hydrogen Generation.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Integrated microfluidic biosensors: shaping the future of quantitative life sciences and on-chip molecular diagnostics.

Lab on a chip·2026
Same author

Hybrid Deep Learning-Machine Learning Fusion of Clinical, Radiomic and Deep Learning Features for Preoperative Differentiation of Solitary Pulmonary Mucinous Adenocarcinoma.

Diagnostics (Basel, Switzerland)·2026
Same author

Coupling external conditions and intrinsic structure in non-noble metal electrocatalysts for the HER/OER.

Nanoscale·2026
Same author

C-terminal interleukin 1 alpha (IL-1α) overexpression drives EMT and a vulnerability to ferroptosis in HNSCC.

Redox biology·2026

Related Experiment Video

Updated: Aug 17, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

SETDB1: A perspective into immune cell function and cancer immunotherapy.

Eleanor Johnson1, Kiarash Salari1, Shujie Yang1,2

  • 1Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

Immunology
|December 16, 2022
PubMed
Summary

The oncogene SET Domain Bifurcated 1 (SETDB1) regulates immune cell function and differentiation. In cancer, SETDB1 overexpression hinders anti-tumor immunity and impacts immunotherapy outcomes.

Keywords:
cancercell differentiationcytokinesregulation/suppressiontumour/immunology

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

592
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K

Related Experiment Videos

Last Updated: Aug 17, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

592
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K

Area of Science:

  • Immunology
  • Epigenetics
  • Cancer Biology

Background:

  • SET Domain Bifurcated 1 (SETDB1), an H3K9 methyltransferase, has known roles in B cell maturation and T cell regulation.
  • SETDB1 is crucial for endogenous retroviruses (ERV) silencing in immune cells.
  • Its functions in immunity were first reported in 2011, despite its earlier discovery.

Purpose of the Study:

  • To review the immunological mechanisms of SETDB1 in normal and cancerous cells.
  • To discuss the implications of SETDB1 in cancer immunotherapy.
  • To elucidate SETDB1's role in immune escape and tumor immunogenicity.

Main Methods:

  • Literature review of studies on SETDB1's immunological functions.
  • Analysis of SETDB1's epigenetic modifications (H3K9 methylation) in immune cells.
  • Examination of SETDB1's impact on gene expression, including ERVs, IL-2, IL-17, and PD-L1.

Main Results:

  • SETDB1 promotes B cell maturation and T cell activity in normal immunity.
  • SETDB1 silences ERVs, which is vital for immune cell function.
  • SETDB1 overexpression in cancer cells impairs anti-tumor immunity by repressing immune cell infiltration and interferon pathways, and affects immunotherapy response.

Conclusions:

  • SETDB1 plays a dual role in immunity: essential for normal function but detrimental when overexpressed in cancer.
  • SETDB1's epigenetic regulation impacts tumor immunogenicity and response to cancer immunotherapies like immune checkpoint blockade.
  • Targeting SETDB1 may offer novel strategies for enhancing cancer immunotherapy.